Efficient Point-of-Care Detection of Uric Acid in the Human Blood Sample with an Enhanced Electrocatalytic Response Using Nanocomposites of Cobalt and Mixed-Valent Molybdenum Sulfide

Abstract

This work efficiently detects uric acid (UA) in a human blood sample using cobalt nanoparticle-immobilized mixed-valent molybdenum sulfide on the copper substrate in a point-of-care (PoC) device. The sensor electrode was fabricated by micromachining of Cu clad boards employing an engraver to generate a three-electrode system consisting of working electrode (WE), reference electrode (RE), and counter electrode (CE). The WE was subjected to physical vapor deposition of mixed-valent MoS_<i>x</i> layers by a reaction between Mo(CO)₆ and H₂S at ∼200 °C using a simple setup following which CoNPs were electrochemically deposited. The RE and CE were covered with Ag/AgCl and Ag paste, respectively. A plasma separation membrane acted as the medium of UA/blood serum delivery to the electrodes. The material and electrochemical characterization confirmed that CoNPs over MoS_<i>x</i> provided an enlarged electroactive surface for the direct electron transfer to achieve an enhanced electrocatalytic response. The binary combination of CoNPs and MoS_<i>x</i> layers over the Cu electrode reduced the charge-transfer resistance by two times, enhanced the surface adsorption by more than two times, and yielded a high diffusion coefficient of 3.46 × 10^-3 cm²/s. These interfacial effects facilitated the UA oxidation, leading to unprecedented mA range current density for UA sensing for the PoC device. The electrochemical detection tests in the PoC device revealed a sensitivity of 64.7 μA/μM cm^-2, which is ∼50 times higher compared to the latest reported value (1.23 μA/μM cm^-2), a high limit of detection of 5 nM, and shelf life of 6 months, confirming the synergistic effect-mediated high sensitivity under PoC settings. Interference tests confirmed no intervention of similar analytes. Tests on blood samples demonstrated a recovery percentage close to 100% in human serum UA, signifying the suitability of the nanocomposite-based sensor and the PoC device for clinical sensing applications.